Switch to:
More From Other Websites
Bank Of America Q3 Small & Mid-Cap Biotech Preview Oct 20 2014
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College... Oct 13 2014
Billionaire Reuben brothers' horseracing group canters to a loss Oct 10 2014
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of... Oct 10 2014
ARENA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Oct 09 2014
Zafgen Aims Obesity Drug At Rare, Deadly Disease Oct 02 2014
[video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment Sep 30 2014
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Sep 22 2014
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Sep 19 2014
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy Sep 16 2014
[video] Orexigen drops in spite of FDA approval Sep 11 2014
U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Sep 11 2014
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised Sep 11 2014
Pharmalot, Pharmalittle: We're Reading About Orexigen, Allergan and Lots More!! Sep 11 2014
Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual... Sep 10 2014
FDA staff: Novo Nordisk drug liraglutide effective for obesity Sep 09 2014
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Sep 03 2014
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension Sep 02 2014
[video] Obesity treatment sales fall short Aug 18 2014
ARENA PHARMACEUTICALS INC Financials Aug 15 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK